HomeCompareAMYT vs MRK

AMYT vs MRK: Dividend Comparison 2026

AMYT yields 13.61% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $7.8K in total portfolio value· pulled ahead in Year 9
10 years
AMYT
AMYT
● Live price
13.61%
Share price
$14.70
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48.9K
Annual income
$3,165.25
Full AMYT calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — AMYT vs MRK

📍 MRK pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMYTMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMYT + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMYT pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMYT
Annual income on $10K today (after 15% tax)
$1,156.46/yr
After 10yr DRIP, annual income (after tax)
$2,690.46/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $5,637.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMYT + MRK for your $10,000?

AMYT: 50%MRK: 50%
100% MRK50/50100% AMYT
Portfolio after 10yr
$52.9K
Annual income
$6,481.70/yr
Blended yield
12.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

AMYT
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$14.50
-1.4% upside vs current
Range: $14.50 — $14.50
Altman Z
0.0
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMYT buys
0
MRK buys
0
No recent congressional trades found for AMYT or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMYTMRK
Forward yield13.61%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$48.9K$56.8K
Annual income after 10y$3,165.25$9,798.13
Total dividends collected$22.3K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$14.50$128.54

Year-by-year: AMYT vs MRK ($10,000, DRIP)

YearAMYT PortfolioAMYT Income/yrMRK PortfolioMRK Income/yrGap
1$12,061$1,360.54$11,206$366.19+$855.00AMYT
2$14,438$1,533.54$12,650$502.35+$1.8KAMYT
3$17,165$1,715.78$14,407$694.19+$2.8KAMYT
4$20,273$1,906.34$16,585$967.82+$3.7KAMYT
5$23,796$2,104.21$19,342$1,363.89+$4.5KAMYT
6$27,770$2,308.32$22,913$1,947.19+$4.9KAMYT
7$32,231$2,517.59$27,662$2,823.89+$4.6KAMYT
8$37,219$2,730.91$34,159$4,173.35+$3.1KAMYT
9← crossover$42,771$2,947.15$43,337$6,308.80$566.00MRK
10$48,930$3,165.25$56,776$9,798.13$7.8KMRK

AMYT vs MRK: Complete Analysis 2026

AMYTStock

Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.

Full AMYT Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this AMYT vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMYT vs SCHDAMYT vs JEPIAMYT vs OAMYT vs KOAMYT vs MAINAMYT vs JNJAMYT vs ABBVAMYT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.